Daniel P Barboriak
Overview
Explore the profile of Daniel P Barboriak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
2046
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ellingson B, Sanvito F, Pope W, Cloughesy T, Huang R, Villanueva-Meyer J, et al.
AJNR Am J Neuroradiol
. 2024 Dec;
46(1):221-222.
PMID: 39730160
No abstract available.
2.
Shiroishi M, Erickson B, Hu L, Barboriak D, Becerra L, Bell L, et al.
Radiology
. 2024 Dec;
313(3):e232555.
PMID: 39656118
The dynamic susceptibility contrast (DSC) MRI measures of relative cerebral blood volume (rCBV) play a central role in monitoring therapeutic response and disease progression in patients with gliomas. Previous investigations...
3.
Ellingson B, Sanvito F, Cloughesy T, Huang R, Villanueva-Meyer J, Pope W, et al.
AJNR Am J Neuroradiol
. 2024 Jun;
45(12):1846-1856.
PMID: 38926092
Radiographic assessment plays a crucial role in the management of patients with central nervous system (CNS) tumors, aiding in treatment planning and evaluation of therapeutic efficacy by quantifying response. Recently,...
4.
Jiang B, Ozkara B, Zhu G, Boothroyd D, Allen J, Barboriak D, et al.
AJNR Am J Neuroradiol
. 2024 Apr;
45(9):1276-1283.
PMID: 38663992
Background And Purpose: Artificial intelligence models in radiology are frequently developed and validated using data sets from a single institution and are rarely tested on independent, external data sets, raising...
5.
Wen P, van den Bent M, Youssef G, Cloughesy T, Ellingson B, Weller M, et al.
J Clin Oncol
. 2023 Sep;
41(33):5187-5199.
PMID: 37774317
Purpose: The Response Assessment in Neuro-Oncology (RANO) criteria for high-grade gliomas (RANO-HGG) and low-grade gliomas (RANO-LGG) were developed to improve reliability of response assessment in glioma trials. Over time, some...
6.
Boxerman J, Snyder B, Barboriak D, Schmainda K
Front Oncol
. 2023 Feb;
13:1061502.
PMID: 36776298
Background: Progressive enhancement predicted poor survival in ACRIN 6677/RTOG 0625, a multi-center trial of bevacizumab with irinotecan or temozolomide in recurrent glioblastoma, but pseudoresponse likely limited enhancement-based survival prognostication in...
7.
Hendrix G, Benjamin R, MacIver N, Barboriak D, Fuchs H, Balikcioglu P
J Endocr Soc
. 2021 Nov;
5(12):bvab160.
PMID: 34765855
No abstract available.
8.
Kaufmann T, Smits M, Boxerman J, Huang R, Barboriak D, Weller M, et al.
Neuro Oncol
. 2020 Aug;
22(11):1706-1707.
PMID: 32823280
No abstract available.
9.
Schmainda K, Prah M, Marques H, Kim E, Barboriak D, Boxerman J
Neuro Oncol
. 2020 Jul;
23(2):314-323.
PMID: 32678438
Background: In Radiation Therapy Oncology Group (RTOG) 0825, a phase III trial of standard therapy with bevacizumab or without (placebo) in newly diagnosed glioblastoma, 44 patients underwent dynamic contrast enhanced...
10.
Boxerman J, Quarles C, Hu L, Erickson B, Gerstner E, Smits M, et al.
Neuro Oncol
. 2020 Jun;
22(9):1262-1275.
PMID: 32516388
Despite the widespread clinical use of dynamic susceptibility contrast (DSC) MRI, DSC-MRI methodology has not been standardized, hindering its utilization for response assessment in multicenter trials. Recently, the DSC-MRI Standardization...